z-logo
open-access-imgOpen Access
Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/ CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent
Author(s) -
Simon Gauvin,
Yannick Cerantola,
Eléonore Haberer,
Vincent Pelsser,
Stephan Probst,
Franck Bladou,
Maurice Anidjar
Publication year - 2017
Publication title -
canadian urological association journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.477
H-Index - 38
eISSN - 1920-1214
pISSN - 1911-6470
DOI - 10.5489/cuaj.4068
Subject(s) - medicine , prostate cancer , positron emission tomography , prostatectomy , nuclear medicine , prostate specific antigen , radiology , context (archaeology) , magnetic resonance imaging , univariate analysis , retrospective cohort study , metastasis , biochemical recurrence , positron emission tomography computed tomography , bone metastasis , prostate , cancer , surgery , multivariate analysis , paleontology , biology
We sought to determine predictive factors (patient and prostate- specific antigen [PSA] characteristics) for 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/ CT) positivity in the context of biochemical recurrence after local treatment of prostate cancer (PCa) with curative intent.Methods: This is a retrospective study including 60 18F-FCH PET/ CT scans of patients with biochemical recurrence after initial radical prostatectomy (RP), external beam radiation therapy (EBRT), or focal high-intensity focused ultrasound (HIFU) with curative intent. The results were compared to findings on magnetic resonance imaging (MRI), computed tomography (CT), bone scan (BS), and histological analysis when available. Univariate analysis was performed to correlate results with patient characteristics.Results: Thirty-eight (63.3%) scans were positive, 17 (28.3%) negative, and 5 (8.3%) equivocal. Of the positive scans, 16 demonstrated local recurrence, 12 regional/distant lymph nodes, five bone metastasis, and five local and distant recurrences. Among the 22 PET/CTs showing metastasis, conventional imaging was performed in 16 patients (72.7%). Of these, it demonstrated the lesion(s) found on PET/CT in eight patients (50.0%), was negative in seven (43.8%), and equivocal in one (6.3%). The trigger PSA (p=0.04), prostate-specific antigen velocity (PSAV) (p=0.03), and prostate-specific antigen doubling time (PSADT) (p=0.046) were significantly different when comparing positive and negative scans. Patients with positive scans were more likely to have received EBRT initially (odds ratio [OR] 11.0, 95% confidence interval [CI] 2.2‒55.3). A trigger PSA of 2.6 ng/mL had a sensitivity of 84% and specificity of 65% for a positive scan. PET/CT changed the clinical management plan in 17 patients (28.3%).Conclusions: 18F-FCH PET/CT demonstrates a high detection rate for local and distant recurrences after localized PCa treatment. A trigger PSA above 2.6 ng/mL seems optimal for appropriate patient selection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here